Ahmad Khan F, Fox G, Menzies D (2017) Drug-resistant tuberculosis BT - Handbook of Antimicrobial Resistance. In: Berghuis A, Matlashewski G, Wainberg MA et al (eds) Springer. New York, NY, New York, pp 263–286 Google Scholar
Alejandra Isabel J-G, Miroslava F-P, Rafael L-L (2019) Second-line injectable drugs for the treatment of multidrug-resistant tuberculosis. Why do we keep using them? Rev Am Med Respir 19:175–178 Google Scholar
Alejandra Isabel J-G, Miroslava F-P, Rafael L-L (2019) Second-line injectable drugs for the treatment of multidrug-resistant tuberculosis. Why do we keep using them? Rev Am Med Respir 3:175–178 Google Scholar
Alemu A, Bitew ZW, Diriba G et al (2023) Incidence and predictors of acquired resistance to second-line antituberculosis drugs during the course of multi-drug resistant tuberculosis treatment: protocol for a systematic review and meta-analysis. BMJ Open 13:e070143. https://doi.org/10.1136/bmjopen-2022-070143 ArticlePubMedPubMed Central Google Scholar
American Diabetes Association Professional Practice Committee (2021) Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes—2022. In: Diabetes Care. American Diabetes Association Professional Practice Committee, pp 46–59
Bakuba Z, Napiórkowska A, Bielecki J et al (2013) Mutations in the embB gene and their association with ethambutol resistance in multidrug-resistant mycobacterium tuberculosis clinical isolates from Poland. Biomed Res Int 2013:1–5. https://doi.org/10.1155/2013/167954 Article Google Scholar
Bollela VR, Namburete EI, Feliciano CS et al (2017) Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis. Int J Tuberc Lung Dis 20:1099–1104. https://doi.org/10.5588/ijtld.15.0864 Article Google Scholar
Brossier F, Pham A, Bernard C et al (2017) Molecular investigation of resistance to second-line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother 61:1–9. https://doi.org/10.1128/AAC.01299-16 Article Google Scholar
Campbell PJ, Morlock GP, Sikes RD et al (2011) Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032–2041. https://doi.org/10.1128/AAC.01550-10 ArticleCASPubMedPubMed Central Google Scholar
CDC (2021) Diagnosis of tuberculosis disease. in: core curriculum on tuberculosis: what the clinician should know. Centers for Disease Control and Prevention, pp 75–107
Chopra H, Mohanta YK, Rauta PR et al (2023) An insight into advances in developing nanotechnology based therapeutics, drug delivery, diagnostics and vaccines: multidimensional applications in tuberculosis disease management. Pharmaceuticals 16:581–617. https://doi.org/10.3390/PH16040581 ArticleCASPubMedPubMed Central Google Scholar
Conkle-Gutierrez D, Kim C, Ramirez-Busby SM et al (2022) Distribution of common and rare genetic markers of second-line-injectable-drug resistance in Mycobacterium tuberculosis revealed by a genome-wide association study. Antimicrob Agents Chemother 66:1–12. https://doi.org/10.1128/AAC.02075-21 Article Google Scholar
Devasia R, Blackman A, Eden S et al (2012) High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol 50:1390–1396. https://doi.org/10.1128/JCM.05286-11 ArticleCASPubMedPubMed Central Google Scholar
Dookie N, Rambaran S, Padayatchi N et al (2018) Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother 73:1138–1151. https://doi.org/10.1093/JAC/DKX506 ArticleCASPubMedPubMed Central Google Scholar
Dookie N, Ngema SL, Perumal R et al (2022) The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives. Clin Microbiol Rev 35:180–219. https://doi.org/10.1128/CMR.00180-19 Article Google Scholar
Dorman SE, Nahid P, Kurbatova EV et al (2020) High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC Study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials 90:105938. https://doi.org/10.1016/J.CCT.2020.105938 ArticlePubMedPubMed Central Google Scholar
Ernest JP, Sarathy J, Wang N et al (2021) Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis. Antimicrob Agents Chemother 65:1–17. https://doi.org/10.1128/AAC.00506-21 Article Google Scholar
Freimane L, Barkāne L, Kivrane A et al (2023) Assessment of amikacin- and capreomycin-related adverse drug reactions in patients with multidrug-resistant tuberculosis and exploring the role of genetic factors. J Pers Med 13:1–12. https://doi.org/10.3390/JPM13040599/S1 Article Google Scholar
Gairola A, Benjamin A, Weatherston JD, et al (2022) Recent developments in drug delivery for treatment of tuberculosis by targeting macrophages. Adv Ther 5:1–49. https://doi.org/10.1002/ADTP.202100193
GE2P2 Global Foundation (2024) The sentinel health, human rights, humanitarian action, hertiage-education, climate-environment, development, peace
Georghiou SB, Magana M, Garfein RS et al (2012) Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:1–12. https://doi.org/10.1371/JOURNAL.PONE.0033275 Article Google Scholar
Institute of Medicine (US) (2013) Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis. National Academies Press, US Google Scholar
Jamal S, Khubaib M, Gangwar R et al (2020) Artificial intelligence and machine learning based prediction of resistant and susceptible mutations in Mycobacterium tuberculosis. Sci Rep 10:1–16. https://doi.org/10.1038/S41598-020-62368-2 Article Google Scholar
K SP, Mani AP, Geethalakshmi S, Yadav S (2024) Advancements in artificial intelligence for the diagnosis of multidrug resistance and extensively drug-resistant tuberculosis: a comprehensive review. Cureus 16:e60280. https://doi.org/10.7759/CUREUS.60280 Article Google Scholar
Khan FA, Salim MAH, du Cros P et al (2017) Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 50:1700061. https://doi.org/10.1183/13993003.00061-2017 ArticleCAS Google Scholar
Kumwenda GP, Chipungu G, Sloan DJ et al (2018) The occurrence and frequency of genomic mutations that mediate isoniazid and rifampicin resistance in Mycobacterium tuberculosis isolates from untreated pulmonary tuberculosis cases in urban Blantyre, Malawi. Malawi Med J 30:1–5. https://doi.org/10.4314/MMJ.V30I1.1 ArticlePubMedPubMed Central Google Scholar
Lai J (2023) Developing a predictive information system for determining the prognosis of HIV and tuberculosis co-infection in incarcerated individuals. Int J Appl Inf Manag 3:101–110. https://doi.org/10.47738/IJAIM.V3I2.55 Article Google Scholar
Le H, Karakasyan C, Jouenne T et al (2021) Application of polymeric nanocarriers for enhancing the bioavailability of antibiotics at the target site and overcoming antimicrobial resistance. Appl Sci 11:10695–10728. https://doi.org/10.3390/APP112210695 ArticleCAS Google Scholar
Lu P, Liu Q, Martinez L et al (2017) Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J 49:1–4. https://doi.org/10.1183/13993003.01558-2016 Article Google Scholar
Ndjeka N, Campbell JR, Meintjes G et al (2022) Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis 22:1042–1051. https://doi.org/10.1016/S1473-3099(21)00811-2 ArticleCASPubMedPubMed Central Google Scholar
Nogueira BMF, Krishnan S, Barreto‐Duarte B, et al (2022) Diagnostic biomarkers for active tuberculosis: progress and challenges. EMBO Mol Med 14:14088. https://doi.org/10.15252/EMMM.202114088
Oehadian A, Santoso P, Menzies D, Ruslami R (2022) Concise clinical review of hematologic toxicity of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis: role of mitochondria. Tuberc Respir Dis (Seoul) 85:111. https://doi.org/10.4046/TRD.2021.0122 ArticlePubMed Google Scholar
Olson S, English R, Claiborne A (2011) Transmission and infection control of drug-resistant TB. In: The new profile of drug-resistant tuberculosis in Russia: a global and local perspective: summary of a joint workshop. National Academies Press (US), Washington (DC), pp 37–47
Padmapriyadarsini C, Vohra V, Bhatnagar A et al (2023) Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis An Off Publ Infect Dis Soc Am 76:e938. https://doi.org/10.1093/CID/CIAC528 Article Google Scholar
Paikray E, Das P, Pattnaik M, Mishra V (2022) Adverse drug reaction monitoring in multidrug-resistant tuberculosis patients receiving bedaquiline and delamanid-based regimen. Cureus 14:1–8. https://doi.org/10.7759/CUREUS.30764 Article Google Scholar
Revised National Tuberculosis Control Programme (2012) Guidelines on programmatic management of drug resistant TB (PMDT) in India control programme guidelines on programmatic management of drug resistant TB ( PMDT ) in India. New Delhi
Revised National Tuberculosis Control Programme (2017) National Strategic Plan For Tuberculosis: 2017-25 Elimination By 2025. New Delhi, India, 1–144
Sahra S (2024b) Tuberculosis (TB) treatment & management: approach considerations, treatment during pregnancy, treatment in children. In: MedScape. https://emedicine.medscape.com/article/230802-treatment. Accessed 7 Aug 2024
Salehitali S, Noorian K, Hafizi M, Dehkordi AH (2019) Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). J Clin Tuberc Other Mycobact Dis 15:1–4. https://doi.org/10.1016/J.JCTUBE.2019.100093 Article Google Scholar
Seung KJ, Keshavjee S, Rich ML (2015b) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Lab Press 5:1–21 CAS Google Scholar
Sinha P, Jacobson KR, Robert HorsburghJr C, Acuña-Villaorduña C (2023) At long last: short, all-oral regimens for multidrug-resistant tuberculosis in the United States. Open Forum Infect Dis 10:1–8. https://doi.org/10.1093/OFID/OFAD177 ArticleCAS Google Scholar
Sowajassatakul A, Prammananan T, Chaiprasert A, Phunpruch S (2014) Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand. BMC Microbiol 14:1–7. https://doi.org/10.1186/1471-2180-14-165 ArticleCAS Google Scholar
Tasnim T, Alam FM, Ahmed SMA et al (2018) gyrA gene mutation conferring phenotypic cross-resistance among fluoroquinolones (ofloxacin, levofloxacin and gatifloxacin) in multidrug resistant Mycobacterium tuberculosis strains isolated from pulmonary MDR-TB patients in Bangladesh. J Tuberc Res 6:227–237. https://doi.org/10.4236/JTR.2018.63021 ArticleCAS Google Scholar
Tavanaee Sani A, Ashna H, Kaffash A et al (2018) Mutations of rpob gene associated with rifampin resistance among Mycobacterium tuberculosis isolated in tuberculosis regional reference laboratory in Northeast of Iran during 2015–2016. Ethiop J Health Sci 28:299–304. https://doi.org/10.4314/EJHS.V28I3.7 ArticlePubMedPubMed Central Google Scholar
Trisakul K, Nonghanphithak D, Chaiyachat P et al (2022) High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates. Emerg Microbes Infect 11:1857–1866. https://doi.org/10.1080/22221751.2022.2099304 ArticleCASPubMedPubMed Central Google Scholar
Tudó G, Rey E, Borrell S et al (2010) Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis clinical isolates in the area of Barcelona. J Antimicrob Chemother 65:2341–2346. https://doi.org/10.1093/JAC/DKQ322 ArticlePubMed Google Scholar
Udwadia ZF, Pinto LM, Uplekar MW (2014) Managerial aspects of the programmatic management of drug-resistant TB. In: Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization, Geneva
USAID (2016) National action plan for combating multidrug-resistant tuberculosis
Vilchèze C, Jr WRJ, Author MS (2019) Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities HHS public access author manuscript. Microbiol Spectr 2:1–21. https://doi.org/10.1128/microbiolspec.MGM2-0014-2013
WHO, The Global Fund To Fight AIDS, Tuberculosis and Malaria STP (2019) Frequently asked questions on the WHO Rapid Communication: key changes to the treatment of multidrug-and rifampicin-resistant TB Prepared by the WHO Task Force to support country transition towards new recommendations for the treatment of MDR-TB
WHO (2011) Guidelines for the programmatic management of drug-resistance tuberculosis. World Heal Organ 1–44
WHO (2014a) Mono- and poly-resistant strains (drug-resistant TB other than MDR-TB). Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization, Geneva, pp 1–27
WHO (2014b) Treatment strategies for MDR-TB and XDR-TB. In: Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, pp 75–99
WHO (2014c) Drug-resistant TB and HIV. In: Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva
WHO (2018) Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). In: World Heal. Organ. https://iris.who.int/handle/10665/275383. Accessed 22 Mar 2024
WHO (2019) WHO consolidated guidelines on drug-resistant tuberculosis treatment
WHO (2020) Consolidated operational guidelines on handbook tuberculosis
WHO (2021c) Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. In: World Heal. Organ. https://www.who.int/publications/i/item/9789240018662. Accessed 22 Mar 2024
WHO (2022a) WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. In: World Heal. Organ. https://www.who.int/publications/i/item/9789240063129. Accessed 22 Mar 2024
WHO (2022b) WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update [Internet]. Geneva: World Health Organization. Recommendations. Available from: https://ncbi.nlm.nih.gov/books/NBK588557/
WHO (2023a) Global tuberculosis report 2023
WHO (2023b) Xpert MTB/RIF and Xpert MTB/RIF ultra assays | TB knowledge sharing. In: WHO TB Knowl. Shar. Platf. https://tbksp.org/en/node/1649. Accessed 22 Mar 2024
WHO (2023c) 5. The 9-month all-oral regimen. In: WHO TB Knowl. Shar. Platf. https://tbksp.org/en/node/582. Accessed 6 Jun 2023
World Health Organization (2008) Guidelines for the programmatic management of drug-resistant tuberculosis Guidelines for the programmatic management of drug-resistant tuberculosis. World Heal Organ 12–185
World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis
World Health Organization (2016a) WHO treatment guidelines for drug-resistant tuberculosis : 2016 update.
World Health Organization (2016b) The shorter MDR-TB regimen
World Health Organization (2018a) WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis. 1–45
World Health Organization (2018b) Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis 2018
World Health Organization (2018c) Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis
World Health Organization (2018d) Rapid communication : key changes to treatment of multidrug- and rifampicin-resistant tuberculosis. World Heal Organ 1–7
World Health Organization (2020a) Global tuberculosis report 2020
World Health Organization (2020b) Consolidated guidelines on tuberculosis treatment
World Health Organization (2022) Global tuberculosis report 2022
Yadav S, Jeyaraman N, Jeyaraman M, Rawal G (2024) Artificial intelligence in tuberculosis diagnosis: revolutionizing detection and treatment. IP Indian J Immunol Respir Med 9:85–87. https://doi.org/10.18231/j.ijirm.2024.017